| Business Summary | | BioMarin
Pharmaceutical
Inc.
develops
enzyme
therapies
to
treat
debilitating,
life-threatening
genetic
diseases
and
other
indications.
The
Company
has
two
enzyme
replacement
therapies
in
clinical
trials
and
recently
filed
an
application
to
enter
a
third
enzyme
into
the
clinic.
Aldurazyme,
a
joint
venture
with
Genzyme
General,
is
an
enzyme
replacement
therapy
in
a
45
patient,
double-blind,
placebo-controlled
Phase
III
clinical
trial
to
treat
Mucopolysaccharidosis
I
(MPS
I),
a
life-threatening
genetic
disease.
On
July
20,
2001,
the
Company
completed
the
24
week
treatment
stage
of
its
Phase
I
clinical
trial
of
rhASB,
an
enzyme
replacement
therapy
for
the
treatment
of
MPS
VI,
a
disease
clinically
similar
to
MPS
I.
Aldurazyme
and
rhASB
have
both
received
fast
track
status
from
the
FDA,
and
they
have
also
each
been
granted
orphan
designations
in
the
U.S.
and
EU.
The
Company
is
also
developing
Vibriolysin
Topical,
an
enzymatic
gel
for
wound
debridement
(cleaning)
in
serious
burn
patients. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | BioMarin
Pharmaceutical
Inc.
develops
enzyme
therapies
to
treat
debilitating,
life-threatening
genetic
diseases
and
other
indications.
For
the
six
months
ended
6/30/01,
revenues
increased
11%
to
$7.1
million.
Net
loss
rose
15%
to
$21.7
million.
Revenues
benefited
from
increased
sales
generated
by
Glyko,
Inc.
Net
loss
reflects
increased
research
and
development
expenses
and
a
higher
equity
in
loss
related
to
BioMarin/Genzyme
LLC. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Fredric Price, 55 Chairman,
CEO | $778K | Raymond Anderson, 59 CFO,
Chief Operating Officer, VP of Fin. and Admin., Sec. | 249K | Robert Baffi, Ph.D., 46 VP,
Quality Assurance and Quality Control | -- | Brian Brandley, Ph.D., 44 VP
of BioMarin and Managing Director, Glyko, Inc. | -- | John Jost, Ph.D., 56 VP,
Manufacturing | 252K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|